{"id":"NCT00281320","sponsor":"Organon and Co","briefTitle":"Study of Asenapine in Elderly Subjects With Psychosis (A7501021)(P05717)","officialTitle":"A Randomized, Parallel Group, Multiple Dose, 6-Week Study to Evaluate Safety, Tolerability, and Pharmacokinetics of Asenapine in Elderly Subjects With Psychosis.","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2006-02","primaryCompletion":"2008-12","completion":"2008-12","firstPosted":"2006-01-24","resultsPosted":"2010-09-09","lastUpdate":"2022-02-09"},"enrollment":122,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"QUADRUPLE","primaryPurpose":"TREATMENT"},"conditions":["Psychosis"],"interventions":[{"type":"DRUG","name":"Asenapine","otherNames":["Saphris"]}],"arms":[{"label":"Asenapine 2-10 mg BID","type":"EXPERIMENTAL"},{"label":"Asenapine 5-10mg BID","type":"EXPERIMENTAL"}],"summary":"This study evaluates the safety and tolerability of Asenapine in elderly patients with psychosis.","primaryOutcome":{"measure":"Number of Participants Who Experienced an Adverse Event","timeFrame":"Up to Day 42 (treatment period)","effectByArm":[{"arm":"Asenapine 2-10 mg Twice Daily (BID)","deltaMin":44,"sd":null},{"arm":"Asenapine 5-10 mg BID","deltaMin":44,"sd":null}],"pValues":[]},"eligibility":{"minAge":"65 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":1,"exclusionCount":2},"locations":{"siteCount":0,"countries":[]},"refs":{"pmids":["21755540"],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":6,"n":61},"commonTop":["Hypertension","Headache","Somnolence","Asthenia","Dizziness"]}}